Differential Activation of ERK Signaling in HPV-Related Oropharyngeal Squamous Cell Carcinoma
Authors:
- Chao RongCRChao Rong
- Marie MullerMMMarie Muller
- Christa FlechtenmacherCFChrista Flechtenmacher
- Dana HolzingerDHDana Holzinger
- Gerhard DyckhoffGDGerhard Dyckhoff
- Olcay Cem BulutOBOlcay Cem Bulut
- Dominik HornDHDominik Horn
- Peter PlinkertPPPeter Plinkert
- Jochen HessJHJochen Hess
- Annette AffolterAAAnnette Affolter
Open Access
Abstract
Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) forms a distinct tumor entity with better survival clinical outcome. Numerous underlying molecular mechanisms have been postulated for differences in treatment response, but the impact of MEK/ERK signaling, a main driver of carcinogenesis in various cancers including OPSCC and key player mediating therapy resistance remains elusive. In a retrospective experimental cohort study, primary tumor samples from OPSCC patients (n = 124) were available on tissue microarrays (TMAs) and expression levels of phosphorylated ERK1/2 (pERK1/2) were detected by immunohistochemical staining. Correlations of pERK1/2 expression patterns with clinicopathological features and clinical outcome were evaluated by statistical analysis. A low pERK1/2 expression was strongly associated with HPV-related OPSCC, while primary tumors with high pERK1/2 staining showed a distinctly worse survival outcome and were associated with higher cellular differentiation. Co-activation of both ERK1/2 and AKT was a common event and was associated with unfavorable prognosis in our cohort. However, the combinatorial analysis of pAKT (Ser473) and pERK1/2 did not strengthen the predictive power of pERK1/2, suggesting that pERK1/2 plays a more significant function in OPSCC. In summary, our data provide a compelling experimental and statistical evidence that low levels of tumor cell intrinsic ERK1/2 activation contribute at least in part to the favorable outcome of HPV-related OPSCC. On the other hand, presented findings indicate that non-HPV-related OPSCC with elevated ERK phosphorylation are at high risk for treatment failure and might benefit from targeted therapy of MEK/ERK signaling.Keywords
This publication has 60 references indexed in Scilit:
- Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trialThe Lancet, 2019
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialThe Lancet, 2019
- The molecular landscape of head and neck cancerNature Reviews Cancer, 2018
- Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?Clinical and Translational Radiation Oncology, 2018
- HPV Associated Head and Neck CancerCancers, 2016
- Epidemiology of Human Papillomavirus–Positive Head and Neck Squamous Cell CarcinomaJournal of Clinical Oncology, 2015
- Identification of a Human Papillomavirus–Associated Oncogenic miRNA Panel in Human Oropharyngeal Squamous Cell Carcinoma Validated by Bioinformatics Analysis of The Cancer Genome AtlasThe American Journal of Pathology, 2015
- The molecular biology of head and neck cancerNature Reviews Cancer, 2010
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- Alcohol Drinking in Never Users of Tobacco, Cigarette Smoking in Never Drinkers, and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology ConsortiumJNCI: Journal of the National Cancer Institute, 2007